Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST-1 & 2)

Edward J Gane, Stephen Pianko, Stuart K Roberts, Alex J Thompson, Stefan Zeuzem, Eli Zuckerman, Ziv Ben Ari, Graham R Foster, Kosh Agarwal, Alex L Laursen, Jan Gerstoft, Wei Gao, Hsueh-Cheng Huang, Brian Fitzgerald, Jerry J Li, Shuyan Wan, Frank Dutko, Bach-Yen T Nguyen, Janice Wahl, Eliav Barr Show all